Canadian Weed Edibles Producer's Q2 Financial Results Show Drop In Revenue & Gross Profit, Here's Why

Canadian cannabis edibles producer Indiva Limited NDVA NDVAF reported on Tuesday its second quarter financial results for the three months ending June 30, 2023.

"This was a transitional and busy quarter for Indiva, with several cross-currents impacting our results, including the negative impact from the loss of revenue from our Indiva Life Lozenges and partial revenue loss in the quarter from the transition to contract manufacturing of Wana gummies, offset by continued growth and excellent market share gains from Pearls by Grön gummies," Niel Marotta, president and CEO of Indiva, said.

Marotta was a guest speaker at Benzinga Cannabis Capital Conference in April 2021. The event returns to Chicago this September and will feature a slew of top cannabis CEOs, executives, entrepreneurs and lawmakers in the space.

Q2 2023 Financial Highlights

  • Gross revenue was CA$ 8.1 million ($5.9 million), representing a 21.6% sequential drop and an 8.5% year-over-year decrease.
  • Net revenue totaled CA$7.5 million, representing a 20.3% sequential decrease and a 7.6% decrease year-over-year.
  • Net revenue from edible products declined to CA$6.9 million, down 6.2% from $7.3 million in the prior quarter and down 5.5% from $7.3 million in the prior year period.
  • Gross profit before fair value adjustments, impairments and one-time items declined year-over-year by 18.2% and quarter-over-quarter by 30.3%, to $CA2.2 million, or 29.3% of net revenue, versus 33.1% in the same quarter of 2022 and 33.6% in the prior period.
  • Operating expenses in the quarter increased 0.2% sequentially and decreased 7.2% year-over-year, representing 43.1% of net revenue, versus 34.3% in the prior period and 42.9% in the corresponding quarter of 2022.
  • Adjusted EBITDA declined sequentially to a loss of CA$600,000, versus a profit of CA$400,000 in the previous quarter and a loss of CA$100,000 in the same quarter of 2022 due to lower sales and lower gross margins.
  • Comprehensive net loss of CA$1 million included a one-time gain of CA$2.1 million on the sale of license rights offset by non-cash charges for impairment of inventory and assets held for sale totaling CA$800,000. Excluding these amounts, comprehensive loss increased to CA$2.3 million versus an adjusted loss of CA$1.3 million in the prior quarter and CA$2 million in the same quarter of 2022.

"While we maintain that the Lozenge products were compliant with the Cannabis Act and had the positive effect of migrating dollars from the illicit market to the legal market, we complied with regulatory orders and discontinued production and packaging of these products in March 2023, and completed all sales of finished goods to provincial wholesalers in May 2023," Marotta continued.

Related News

The Benzinga Cannabis Capital Conference, the place where deals get done, is returning to Chicago this Sept 27-28 for its 17th edition. Get your tickets today before prices increase and secure a spot at the epicenter of cannabis investment and branding.

Photo: Courtesy of Hvoenok and GOR Photo on Shutterstock

Market News and Data brought to you by Benzinga APIs
Actual EPS
EPS Surprise
Actual Rev
Rev Surprise
Posted In: CannabisEarningsNewsPenny StocksMarketsCCCfinancia resultsmarijuana salesNiel Marottapremiumsecond quarter earnings report
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!

The Top Cannabis Event In New Jersey

Join the Benzinga Cannabis Market Spotlight in New Jersey on June 17th! Grow your business, raise money and capitalize on the booming NJ recreational market. Don’t miss this must-attend event in New Brunswick. Secure your tickets now. Very few spots are left. Use the code "JAVIER20" for 20% off!